PDEX

Business Context and Reporting Period

Company: PRO-DEX, INC. (PDEX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended September 30, 2025 (First Quarter of Fiscal 2026)
Business Overview: Pro-Dex designs, develops, and manufactures autoclavable, battery-powered, and electric surgical drivers and shavers primarily for orthopedic, thoracic, and maxocranial facial (CMF) markets. The company also provides engineering and regulatory consulting services.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 24% ($3.6M) driven by a 45% increase in medical device sales, specifically a 65% rise in orthopedic sales due to the launch of a next-generation handpiece for the largest customer.
• Margin Compression: Gross margin declined from 35% to 29%. Management attributed this to higher product costs, including tariffs not yet fully passed to customers, and lower margins on repair services due to expensive component replacements.
• Investment Gains: Net income surged 90% largely due to a $3.3 million unrealized gain on marketable equity investments, compared to $0.4 million in the prior year. This gain is primarily related to the investment in Monogram Technologies, Inc.
• Debt Reduction: Total notes payable decreased by $2.2 million to $13.3 million due to principal payments on UMB Bank loans.
• Customer Concentration: Customer concentration remains high. One customer accounted for 78% of total sales and 84% of accounts receivable.

Guidance, Outlook, and Risks

• Subsequent Event (Monogram Acquisition): On October 7, 2025, Zimmer Biomet acquired Monogram Technologies. Pro-Dex received $8.9 million in cash proceeds and expects to record a realized gain of $6.8 million in Q2 2026. Pro-Dex also received contingent value rights (CVRs) with a potential value of up to $12.4 million if specific milestones are met.
• Backlog: As of September 30, 2025, the company reported a backlog of approximately $46.8 million, with $43.6 million scheduled for delivery in the remainder of fiscal 2026.
• Contract Negotiations: Pro-Dex is negotiating an extension of its supply agreement with its largest customer through calendar 2028. The customer has placed orders through the end of calendar 2026.
• New Product Launch: The Helios driver for CMF applications is expected to be released for production in Q2 2026.
• Risks:
  • Customer Dependency: Heavy reliance on a single customer (78% of sales) creates significant concentration risk.
  • AI Misinformation: A law firm recently issued a press release containing erroneous information attributed to AI regarding the company's stock price, highlighting risks of misinformation.
  • Symbol Confusion: Potential confusion exists between Pro-Dex (PDEX) and Polkadex (a cryptocurrency also using the PDEX symbol).

Investor Verification Checklist

• Monogram Realized Gain: Verify the timing and accounting treatment of the $6.8 million realized gain from the Monogram acquisition in Q2 2026.
• Customer Contract Extension: Monitor the status of negotiations to extend the supply agreement with the largest customer (78% of revenue) beyond 2025.
• Gross Margin Recovery: Assess whether the company can pass on tariff and component cost increases to restore gross margins to historical levels (35%+).
• Contingent Value Rights (CVRs): Review the likelihood of achieving the five milestones required to unlock the potential $12.4 million in CVR payments.
• Debt Covenants: Confirm continued compliance with UMB Bank debt covenants, particularly given the company's reliance on operating cash flow and investment gains.